Efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Yangqing ¹ ,  WANG Yanfang ² , GUO Lijun ³

1. Henan University People's Hospital, Zhengzhou 450003, P.R.China;
2. Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou 450003, P.R.China;
3. Jinzhou Medical University, Jinzhou 121000, P.R.China;

Corresponding author：

WANG Yanfang, Email: yfwang612@126.com

Keywords：

Bailing capsule; Hashimoto thyroiditis; Autoimmune antibodies; Meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.201904064

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis (HT).Methods PubMed, EMbase, The Cochrane Library, CBM, WanFang Data and CNKI databases were electronically searched to collect the randomized controlled trials (RCTs) on Bailing capsule in treatment of HT from inception to January 2019. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.Results A total of 7 RCTs involving 428 patients were included. The results of meta-analysis showed that the changes of TGAb and TPOAb in Bailing capsule combined with Euthyrox group were higher than that in control group (MD=−228.91, 95%CI −398.61 to −59.20, P=0.008; MD=−158.19, 95%CI −222.44 to −93.94, P<0.000 01); the changes of TGAb and TPOAb in Bailing capsule combined with Iodine modification diet group were higher than that in control group(MD=−499.27, 95%CI −540.39 to −458.15, P<0.000 01; MD=−407.37, 95%CI −448.60 to −366.14, P<0.000 01).Conclusions Current evidence shows that Bailing capsule combined with other therapies can decrease the levels of TGAb and TPOAb in HT patients. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusion.

Citation： LIU Yangqing, WANG Yanfang, GUO Lijun. Efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2020, 20(4): 453-457. doi: 10.7507/1672-2531.201904064 Copy

1.	Semiz H, Yalcin M, Kobak S. Coexistence of sarcoidosis and Hashimoto thyroiditis. Reumatismo, 2018, 70(2): 106-110.
2.	Abbott RD, Sadowski A, Alt AG. Efficacy of the autoimmune protocol diet as part of a multi-disciplinary, supported lifestyle intervention for hashimoto's thyroiditis. Cureus, 2019, 11(4): e4556.
3.	Krysiak R, Kowalcze K, Okopień B. The effect of vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and testosterone deficiency. Pharmacol Rep, 2019, 71(5): 798-803.
4.	中华医学会内分泌学分会. 中国甲状腺疾病诊治指南—甲状腺炎. 中华内科杂志, 2008, 47(9): 784-788.
5.	Liu C. Chronic lymphocytic thyroiditis. Int J Endocrinol Metab, 2009, 29(1): 57-59.
6.	Brix TH, Laszlo H. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol, 2012, 76(4): 457-464.
7.	Ren HJ, Sun YL, Yuan B. Chinese patent medicine Bailing capsule for treating lupus nephritis: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(37): e17041.
8.	王新, 王静. 百令胶囊辅助治疗对稳定期 COPD 患者气道功能及血清气道重塑分子的影响. 中国现代医学杂志, 2019, 29(6): 88-91.
9.	祝明, 金樟照, 陈勇, 等. 百令胶囊的指纹图谱鉴别研究. 中成药, 2007, 29(9): 1254-1256.
10.	杨立娜, 丁萌, 张翠兰, 等. 不同剂量百令胶囊联合左甲状腺素治疗桥本甲状腺炎的临床研究. 现代药物与临床, 2018, 33(5): 1193-1197.
11.	He T, Zhao R, Lu Y, et al. Dual-directional immunomodulatory effects of Corbin capsule on autoimmune thyroid diseases. Evid Based Complement Alternat Med, 2016, 2016: 1360386.
12.	迪丽卡麦尔·艾沙. 优甲乐联合硒维尔与百令胶囊对桥本氏甲状腺炎并甲减患者的 (Anti-TPO, Anti-TG) 抗体水平比较. 南昌: 南昌大学, 2016.
13.	范莉萍. 百令胶囊对桥本氏甲减免疫功能及甲状腺功能的影响. 长春: 吉林大学, 2014.
14.	刘宝忠, 张花, 杨坤, 等. 百令胶囊对桥本甲状腺炎患者自身免疫性抗体的影响. 医药导报, 2009, 28(6): 727-728.
15.	李淑文. 百令胶囊对桥本甲状腺炎患者自身免疫性抗体的影响. 中国药物经济学, 2017, 12(10): 57-59.
16.	张玮. 百令胶囊对桥本氏甲状腺炎患者过氧化物酶抗体的影响. 实用临床医学, 2015, 16(4): 23-24.
17.	汪新宇, 王桂兰, 田志刚. Th1/Th2 亚群与自身免疫性甲状腺疾病. 中华内分泌代谢杂志, 2001, 17(2): 124-125.
18.	赵闫丽, 黄琦. 桥本甲状腺炎 Th1/Th2 偏移的研究及治疗进展. 浙江中医药大学学报, 2014, (1): 107-109.
19.	许峥嵘, 李昭瑛. 桥本甲状腺炎与 Th1/Th2 细胞因子. 医学综述, 2006, 12(24): 1492-1493.
20.	陶征, 吴洁, 李连喜. 自身免疫性甲状腺疾病甲状腺自身抗体的临床研究. 江苏大学学报 (医学版), 2004, 14(2): 123-125, 129.
21.	陶静芬, 朱明风, 叶根娟, 等. 血清 TPOAb 与 TMA、TGA 在桥本氏甲状腺炎诊断中的临床意义. 放射免疫学杂志, 2000, 13(5): 299-300.
22.	Stott DJ, Gussekloo J, Kearney PM, et al. Study protocol: thyroid hormone replacement for untreated older adults with subclinical hypothyroidism-a randomised placebo controlled trial (TRUST). BMC Endocr Disord, 2017, 17(1): 6.
23.	韩静, 刘守尧. 桥本氏甲状腺炎中西医治疗研究进展. 中华中医药杂志, 2019, 34(11): 5327-5330.
24.	孙忠华, 肖建辉. 虫草属真菌的生物活性. 中药材, 2013, 36(7): 1183-1189.
25.	许惠娟, 李时悦. 百令胶囊的药理作用及其在肺部疾病的研究进展. 中国中药杂志, 2010, 35(20): 2777-2781.
26.	李晓雯, 廖春分, 陈思思, 等. 百令胶囊口服联合曲安奈德局部注射治疗桥本氏甲状腺炎的疗效观察. 中南医学科学杂志, 2016, 44(3): 319-322.

1. Semiz H, Yalcin M, Kobak S. Coexistence of sarcoidosis and Hashimoto thyroiditis. Reumatismo, 2018, 70(2): 106-110.
2. Abbott RD, Sadowski A, Alt AG. Efficacy of the autoimmune protocol diet as part of a multi-disciplinary, supported lifestyle intervention for hashimoto's thyroiditis. Cureus, 2019, 11(4): e4556.
3. Krysiak R, Kowalcze K, Okopień B. The effect of vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and testosterone deficiency. Pharmacol Rep, 2019, 71(5): 798-803.
4. 中华医学会内分泌学分会. 中国甲状腺疾病诊治指南—甲状腺炎. 中华内科杂志, 2008, 47(9): 784-788.
5. Liu C. Chronic lymphocytic thyroiditis. Int J Endocrinol Metab, 2009, 29(1): 57-59.
6. Brix TH, Laszlo H. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol, 2012, 76(4): 457-464.
7. Ren HJ, Sun YL, Yuan B. Chinese patent medicine Bailing capsule for treating lupus nephritis: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(37): e17041.
8. 王新, 王静. 百令胶囊辅助治疗对稳定期 COPD 患者气道功能及血清气道重塑分子的影响. 中国现代医学杂志, 2019, 29(6): 88-91.
9. 祝明, 金樟照, 陈勇, 等. 百令胶囊的指纹图谱鉴别研究. 中成药, 2007, 29(9): 1254-1256.
10. 杨立娜, 丁萌, 张翠兰, 等. 不同剂量百令胶囊联合左甲状腺素治疗桥本甲状腺炎的临床研究. 现代药物与临床, 2018, 33(5): 1193-1197.
11. He T, Zhao R, Lu Y, et al. Dual-directional immunomodulatory effects of Corbin capsule on autoimmune thyroid diseases. Evid Based Complement Alternat Med, 2016, 2016: 1360386.
12. 迪丽卡麦尔·艾沙. 优甲乐联合硒维尔与百令胶囊对桥本氏甲状腺炎并甲减患者的 (Anti-TPO, Anti-TG) 抗体水平比较. 南昌: 南昌大学, 2016.
13. 范莉萍. 百令胶囊对桥本氏甲减免疫功能及甲状腺功能的影响. 长春: 吉林大学, 2014.
14. 刘宝忠, 张花, 杨坤, 等. 百令胶囊对桥本甲状腺炎患者自身免疫性抗体的影响. 医药导报, 2009, 28(6): 727-728.
15. 李淑文. 百令胶囊对桥本甲状腺炎患者自身免疫性抗体的影响. 中国药物经济学, 2017, 12(10): 57-59.
16. 张玮. 百令胶囊对桥本氏甲状腺炎患者过氧化物酶抗体的影响. 实用临床医学, 2015, 16(4): 23-24.
17. 汪新宇, 王桂兰, 田志刚. Th1/Th2 亚群与自身免疫性甲状腺疾病. 中华内分泌代谢杂志, 2001, 17(2): 124-125.
18. 赵闫丽, 黄琦. 桥本甲状腺炎 Th1/Th2 偏移的研究及治疗进展. 浙江中医药大学学报, 2014, (1): 107-109.
19. 许峥嵘, 李昭瑛. 桥本甲状腺炎与 Th1/Th2 细胞因子. 医学综述, 2006, 12(24): 1492-1493.
20. 陶征, 吴洁, 李连喜. 自身免疫性甲状腺疾病甲状腺自身抗体的临床研究. 江苏大学学报 (医学版), 2004, 14(2): 123-125, 129.
21. 陶静芬, 朱明风, 叶根娟, 等. 血清 TPOAb 与 TMA、TGA 在桥本氏甲状腺炎诊断中的临床意义. 放射免疫学杂志, 2000, 13(5): 299-300.
22. Stott DJ, Gussekloo J, Kearney PM, et al. Study protocol: thyroid hormone replacement for untreated older adults with subclinical hypothyroidism-a randomised placebo controlled trial (TRUST). BMC Endocr Disord, 2017, 17(1): 6.
23. 韩静, 刘守尧. 桥本氏甲状腺炎中西医治疗研究进展. 中华中医药杂志, 2019, 34(11): 5327-5330.
24. 孙忠华, 肖建辉. 虫草属真菌的生物活性. 中药材, 2013, 36(7): 1183-1189.
25. 许惠娟, 李时悦. 百令胶囊的药理作用及其在肺部疾病的研究进展. 中国中药杂志, 2010, 35(20): 2777-2781.
26. 李晓雯, 廖春分, 陈思思, 等. 百令胶囊口服联合曲安奈德局部注射治疗桥本氏甲状腺炎的疗效观察. 中南医学科学杂志, 2016, 44(3): 319-322.

Chinese Journal of Evidence-Based Medicine

Efficacy of Bailing capsule for autoimmune antibodies in Hashimoto thyroiditis: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content